The Relation Between Dedicated Extremity MRI Synovitis and Structural Deterioration Radiographic in Patients With Rheumatoid Arthritis in Clinical Remission. Preliminary Study

The Relation Between Dedicated Extremity MRI Synovitis and Structural Deterioration Radiographic in Patients With Rheumatoid Arthritis in Clinical Remission.Preliminary Study

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01050010

Enrollment

Registered

2010-01-15

Start date

2010-04-30

Completion date

2012-04-30

Last updated

2011-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Keywords

rheumatoid arthritis, clinical remission, synovitis, dedicated extremity MRI

Brief summary

The major aim of treatment for rheumatoid arthritis is remission. Nevertheless, structural radiographic progression is observed in 15 to 20% of patient getting remission. Numerous definitions of the remission proposed by literature remain imperfect. Recently ultrasonography and MRI seem to be helpful in diagnosis and follow-up of rheumatoid arthritis. Studies in patients with clinical remission are reporting 75 to 90% of persistent MRI and ultrasonography synovitis, 45% of cases with synovial activity. To our knowledge, in such case few studies showed correlation between persistent imaging synovitis and structural radiographic progression. On the other hand, no studies with extremity dedicated RMI in patients with remission are reported. In this preliminary study, the investigators propose to evaluate in patients with rheumatoid arthritis remission and persistent dedicated MRI synovitis the structural radiographic progression at one year.

Interventions

OTHERMRI

dedicated extremity MRI

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

SCREENING

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Earlier rheumatoid arthritis (\<1 year) * Clinical remission (DAS 28 \<2,6 ou SDAI \<5) since 6 months before the inclusion * Unchanged DMARds and /or biologic therapy since 6 months before the inclusion * Unchanged corticosteroid (5 mg/day) since 3 months before the inclusion in patients treated with this therapy * No contre-indication to the MRI

Exclusion criteria

* Contra-indication to MRI * Pregnant or breast-feeding women

Design outcomes

Primary

Measure	Time frame
Dedicated extremity MRI (hand and wrist)/ X-Ray (hand, wrist and foot)	at Month 0 (first visit) and Month 12 (last visit)

Secondary

Measure	Time frame
Ultrasonography (hand, wrist and foot)	at Month 0 (first vist) and Month 12 (last visit)

Countries

France

Contacts

Primary ContactChristine ALBERT-SABONNADIERE, PhD

albert-sabonnadiere.c@chu-nice.fr

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026